ClinicalTrials.gg
TerminatedNCT05151471Updated Oct 21, 2026Results posted

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

A Phase 3 interventional study of MT-1186 and Placebo in ALS, sponsored by Shionogi. Terminated at 37 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Why this study was terminated
Futility Analysis of parent study MT-1186-A02 was met.
Updated Oct 21, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in Study MT-1186-A02 to at least a 12-point decrease in Revised ALS Functional Rating Score (ALSFRS-R) or death, whichever happens first, over the course of the study or until oral edaravone is commercially available in that country

02

Conditions studied

  • ALS
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects or their legally authorized representative must provide a signed and dated form to participate in the study.
  2. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study.
  3. Subjects must be willing to cooperate and comply with all protocol restrictions and requirements.
  4. Subjects must have successfully completed all Study MT-1186-A02 visits and have been compliant with study drug.

Exclusion criteria

Exclusion Criteria:

  1. Subjects of unwilling to use an acceptable method of from the Day 1/screening visit until 3 months after the last dose of study medication. Subjects who are sexually active who do not agree to use contraception during the study period.
  2. Subjects who are female, of childbearing potential, and pregnant (a positive pregnancy test) or lactating at the Day 1/screening visit.
  3. Subjects who have a significant risk of suicide. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) at Week 48 of Study MT-1186-A02.
  4. Subjects who are not eligible to continue in the study, as judged by the Investigator in conjunction with the MTDA medical monitor.
  5. Subjects who are unable to take their medications orally or through a PEG/RIG tube.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    MT-1186 - Group 1

    Oral edaravone administered once daily for up to 48 weeks or until the drug is commercially available in that country.

    Drug: MT-1186

  • Experimental
    MT-1186 - Group 2

    Oral edaravone administered for 10 days followed by 18-day placebo (regimen denoted as on/off) for up to 48 weeks or until the drug is commercially available in that country.

    Drug: MT-1186 · Drug: Placebo

Interventions

  • DrugMT-1186

    Oral edaravone

    Also known as: Oral edaravone

  • DrugPlacebo

    Oral

    Also known as: Oral

06

What researchers measure

Primary outcomes

  1. Time From the Randomization Date in Study MT-1186-A02 to at Least a 12-point Decrease in ALSFRS-R or Death, Whichever Happens First.

    The ASLFRS-R is Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised. The ALSFRS-R measures 12 aspects of physical function, ranging from one's ability to swallow and use utensils to climbing stairs and breathing. Each function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0.

    Time frame: Up to 96 weeks

Secondary outcomes

  1. The Combined Assessment of Function and Survival (CAFS) Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04

    CAFS analysis ranks clinical outcomes on the basis of survival time and change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. A subject's score will be calculated by comparing each subject to every other subject within each treatment group in the study, resulting in a score of +1 if the outcome was better than the subject being compared, -1 if worse, and 0 if the same. The subject's score will then be calculated by summing up their comparison to all of the other subjects within each treatment group in the study as CAFS score. Patients' summary scores are ranked; a higher score indicates a better performance. The score range is from 1 to N, where N is the total sample size. Since CAFS were calculated using the imputed ALSFRS-R scores with multiple imputation method, and the maximum varies for each simulation, 383 is the maximum possible value of full range for measure of dispersion.

    Time frame: Baseline, Week 72 and Week 96

  2. Change in the Amyotrophic Lateral Sclerosis Assessment Questionnaire 40 Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04

    The ALSAQ-40 is a questionnaire that consists of 40 questions/items with 5 discrete scales: physical mobility, activities of daily living and independence, eating and drinking, communication, emotional reactions, ranging from 0 (best health as assessed by the scale) to 100 (worse health as assessed by the measure).

    Time frame: Baseline, Week 72 and Week 96

  3. Change in ALSFRS-R Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04

    The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.

    Time frame: Baseline, Week 72, Week 84 and Week 96

  4. Time From the Randomization Date in Study MT-1186-A02 to Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation (≥23 Hours/Day)

    Time frame: Up to 96 weeks

  5. Time From the Randomization Date in Study MT-1186-A02 to Death or Permanent Assisted Mechanical Ventilation (>23 Hours/Day)

    Time frame: Up to 96 weeks

  6. Time From the Randomization Date in Study MT-1186-A02 to Death

    Time frame: Up to 96 weeks

07

Results

Posted Mar 27, 2025

Participant flow

Participant flow — Overall Study
MilestoneEdaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)
Started10498
Completed2424
Not completed8074
Withdrew: Adverse event2116
Withdrew: Death10
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject79
Withdrew: Study terminated by sponsor4947
Withdrew: Other21

Outcome measures

PrimaryTime From the Randomization Date in Study MT-1186-A02 to at Least a 12-point Decrease in ALSFRS-R or Death, Whichever Happens First.

The ASLFRS-R is Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised. The ALSFRS-R measures 12 aspects of physical function, ranging from one's ability to swallow and use utensils to climbing stairs and breathing. Each function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0.

Time frame:
Up to 96 weeks
Reported as:
Mean · Month
Time From the Randomization Date in Study MT-1186-A02 to at Least a 12-point Decrease in ALSFRS-R or Death, Whichever Happens First.
MonthEdaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)
Time From the Randomization Date in Study MT-1186-A02 to at Least a 12-point Decrease in ALSFRS-R or Death, Whichever Happens First.13.9 (13.4 to 16.59)15.05 (13.8 to 16.62)
Statistical analysis
  • Edaravone 105 mg (Once Daily) vs Edaravone 105 mg (on/Off) · Log Rank · p = 0.78
SecondaryThe Combined Assessment of Function and Survival (CAFS) Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04

CAFS analysis ranks clinical outcomes on the basis of survival time and change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. A subject's score will be calculated by comparing each subject to every other subject within each treatment group in the study, resulting in a score of +1 if the outcome was better than the subject being compared, -1 if worse, and 0 if the same. The subject's score will then be calculated by summing up their comparison to all of the other subjects within each treatment group in the study as CAFS score. Patients' summary scores are ranked; a higher score indicates a better performance. The score range is from 1 to N, where N is the total sample size. Since CAFS were calculated using the imputed ALSFRS-R scores with multiple imputation method, and the maximum varies for each simulation, 383 is the maximum possible value of full range for measure of dispersion.

Time frame:
Baseline, Week 72 and Week 96
Reported as:
Mean · units on a scale
The Combined Assessment of Function and Survival (CAFS) Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04
units on a scaleEdaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)
Week 72193.6 (4 to 383)189.1 (1 to 383)
Week 96200.8 (4 to 383)181.6 (1 to 383)
Statistical analysis
  • Edaravone 105 mg (Once Daily) vs Edaravone 105 mg (on/Off) · ANCOVA · p = 0.704
  • Edaravone 105 mg (Once Daily) vs Edaravone 105 mg (on/Off) · ANCOVA · p = 0.131
SecondaryChange in the Amyotrophic Lateral Sclerosis Assessment Questionnaire 40 Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04

The ALSAQ-40 is a questionnaire that consists of 40 questions/items with 5 discrete scales: physical mobility, activities of daily living and independence, eating and drinking, communication, emotional reactions, ranging from 0 (best health as assessed by the scale) to 100 (worse health as assessed by the measure).

Time frame:
Baseline, Week 72 and Week 96
Reported as:
Least squares mean · Point
Change in the Amyotrophic Lateral Sclerosis Assessment Questionnaire 40 Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04
PointEdaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)
Week 7245.71 ± 3.1445.46 ± 3.11
Week 9654.83 ± 4.0557.91 ± 4.13
Statistical analysis
  • Edaravone 105 mg (Once Daily) vs Edaravone 105 mg (on/Off) · Mixed Model for Repeated Measures (MMRM) · p = 0.954
  • Edaravone 105 mg (Once Daily) vs Edaravone 105 mg (on/Off) · Mixed Model for Repeated Measures (MMRM) · p = 0.591
SecondaryChange in ALSFRS-R Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04

The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.

Time frame:
Baseline, Week 72, Week 84 and Week 96
Reported as:
Least squares mean · Point
Change in ALSFRS-R Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04
PointEdaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)
Week 72-15.02 ± 0.95-15.90 ± 0.95
Week 84-16.79 ± 1.11-18.27 ± 1.10
Week 96-18.21 ± 1.31-20.95 ± 1.32
Statistical analysis
  • Edaravone 105 mg (Once Daily) vs Edaravone 105 mg (on/Off) · Mixed Model for Repeated Measures (MMRM) · p = 0.513
  • Edaravone 105 mg (Once Daily) vs Edaravone 105 mg (on/Off) · Mixed Model for Repeated Measures (MMRM) · p = 0.344
  • Edaravone 105 mg (Once Daily) vs Edaravone 105 mg (on/Off) · Mixed Model for Repeated Measures (MMRM) · p = 0.142
SecondaryTime From the Randomization Date in Study MT-1186-A02 to Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation (≥23 Hours/Day)
Time frame:
Up to 96 weeks
Reported as:
Median · Month
Time From the Randomization Date in Study MT-1186-A02 to Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation (≥23 Hours/Day)
MonthEdaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)
Time From the Randomization Date in Study MT-1186-A02 to Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation (≥23 Hours/Day)NA (19.36 to 21.02)NA (19.43 to 21.13)
SecondaryTime From the Randomization Date in Study MT-1186-A02 to Death or Permanent Assisted Mechanical Ventilation (>23 Hours/Day)
Time frame:
Up to 96 weeks
Reported as:
Median · Month
Time From the Randomization Date in Study MT-1186-A02 to Death or Permanent Assisted Mechanical Ventilation (>23 Hours/Day)
MonthEdaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)
Time From the Randomization Date in Study MT-1186-A02 to Death or Permanent Assisted Mechanical Ventilation (>23 Hours/Day)NA (NA to NA)NA (NA to NA)
SecondaryTime From the Randomization Date in Study MT-1186-A02 to Death
Time frame:
Up to 96 weeks
Reported as:
Median · Month
Time From the Randomization Date in Study MT-1186-A02 to Death
MonthEdaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)
Time From the Randomization Date in Study MT-1186-A02 to DeathNA (NA to NA)NA (NA to NA)

Adverse events

Collected over Up to 50 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Edaravone 105 mg (Once Daily)15/104 (14.4%)33/104 (31.7%)24/104 (23.1%)
Edaravone 105 mg (on/Off)12/98 (12.2%)27/98 (27.6%)25/98 (25.5%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventEdaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)
DysphagiaGastrointestinal disorders14/1045/98
Respiratory failureRespiratory, thoracic and mediastinal disorders10/10410/98
Amyotrophic lateral sclerosisNervous system disorders4/1041/98
FallInjury, poisoning and procedural complications0/1042/98
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders2/1042/98
COVID-19Infections and infestations2/1041/98
PneumoniaInfections and infestations2/1041/98
Cardiac arrestCardiac disorders0/1041/98
Catheter site infectionInfections and infestations0/1041/98
Extradural haematomaInjury, poisoning and procedural complications0/1041/98
Most frequent other events
Most frequent other events
EventEdaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)
FallInjury, poisoning and procedural complications8/10413/98
ConstipationGeneral disorders7/1046/98
COVID-19Infections and infestations6/1041/98
DiarrhoeaGeneral disorders4/1045/98
InsomniaPsychiatric disorders5/1045/98

Baseline characteristics

The data collected before the first study drug dose administration date in Study MT-1186-A02 will be used as the baseline for statistical analysis in Study MT-1186-A04.

Age, Customized
Age, Customized(Participants)Edaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)Total
Adults (18-64 years)134122256
From 65-84 years5870128
Sex: Female, Male
Sex: Female, Male(Participants)Edaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)Total
Female6970139
Male123122245
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Edaravone 105 mg (Once Daily)Edaravone 105 mg (on/Off)Total
White115109224
Black or African American325
Asian - Japanese6364127
Asian - Not Japanese81321
American Indian or Alaska Native011
Native Hawaiian or Pacific Islander011
Not Reported011
Other314
08

Study locations

37 sites
  • Woodland Research Northwest, LLC
    Rogers, Arkansas 72758, United States
  • UF Health Cancer Center/Clinical Trials Office
    Gainesville, Florida 32610-3633, United States
  • Emory University - School of Medicine
    Atlanta, Georgia 30317-2819, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611-2605, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Neurology Associates, P.C - Lincoln
    Lincoln, Nebraska 68506, United States
  • University Of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Nerve And Muscle Center Of Texas
    Houston, Texas 77019, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • West Virginia University School of Medicine (WVUSoM) - Movement Disorder Clinic
    Morgantown, West Virginia 26506-9180, United States
  • University of Alberta - Walter C Mackenzie Health Sciences Centre (WCM)
    Edmonton, Alberta T6G 2B7, Canada
  • Health Science Center Mcmaster University
    Hamilton, Ontario L8P 1H1, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • CHU de Quebec-Hopital-Enfant-Jesus
    Québec, Quebec G1J 1Z4, Canada
  • Universitaetsklinikum Wuerzburg
    Würzburg, 97080, Germany
  • National Hospital Organization Higashinagoya National Hospital
    Nagoya, Aichi-ken 465-8620, Japan
  • Nagoya University Hospital
    Nagoya, Aichi-ken 466-8560, Japan
  • National Hospital Organization Chibahigashi National Hospital
    Chiba, Chiba 260-8712, Japan
  • Murakami Karindoh Hospital
    Fukuoka, Fukuoka 819-8585, Japan
  • Fukushima Medical University Hospital
    Fukushima, Fukushima 960-1295, Japan
  • Hiroshima University Hospital
    Hiroshima, Hiroshima 734-8551, Japan
  • National Hospital Organization Iou National Hospital
    Kanazawa, Ishikawa-ken 920-0192, Japan
  • Kagawa University Hospital
    Kita-gun, Kagawa-ken 761-0793, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
  • National Hospital Organization Kumamoto Saishun Medical Center
    Kōshi, Kumamoto 861-1196, Japan
  • National Hospital Organization Utano National Hospital
    Kyoto, Kyoto 616-8255, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Niigata University Medical & Dental Hospital
    Niigata, Niigata 951-8520, Japan
  • Kansai Electric Power Hospital
    Osaka, Osaka 553-0003, Japan
  • National Hospital Organization Osaka Toneyama Medical Center
    Toyonaka, Osaka 560-8552, Japan
  • National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders
    Shizuoka, Shizuoka 420-8688, Japan
  • Tokyo Metropolitan Neurological Hospital
    Fuchū, Tokyo 183-0042, Japan
  • Teikyo University Hospital
    Itabashi-ku, Tokyo 173-8606, Japan
  • Toho University Omori Medical Center
    Ōta-ku, Tokyo 143-8541, Japan
  • Saitama Neuropsychiatric Institute
    Saitama, 338-8577, Japan
  • Hanyang University Medical Center
    Wangsimni-ro, Seongdong-gu 04763, South Korea
  • Chefarzt Muskelzentrum/ALS Clinic Kantonsspital St.Gallen Muskelzentrum/ALS Clinic
    Sankt Gallen, 9007, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Sep 2023, 20 months.

Results were first posted in Mar 2025, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2021
First posted
Dec 9, 2021
StartActual
Jan 11, 2022
Primary completionActual
Sep 29, 2023
CompletionActual
Sep 29, 2023
Results first posted
Mar 27, 2025
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 21, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionThe Combined Assessment of Function and Survival (CAFS) Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04: how it is measured was reworded
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Posted results revised
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionThe Combined Assessment of Function and Survival (CAFS) Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05151471
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Jan 11, 2022
Primary completion
Sep 29, 2023
Completion
Sep 29, 2023
Results posted
Mar 27, 2025
Last update
Oct 21, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion